Kestra Medical Technologies' (KMTS) "Buy" Rating Reaffirmed at BTIG Research

Key Points

• BTIG reaffirmed its "Buy" on Kestra Medical Technologies (KMTS) with a $32 price target, implying roughly a 65.63% upside from the prior close.
• Analysts are mixed — three Buy, one Hold and one Sell — leaving a MarketBeat consensus rating of Hold and an average price target of $28.80.
• Kestra reported Q EPS of ($0.61), missing estimates by $0.01 while revenue rose 62.7% to $24.55M; the company remains unprofitable (negative ROE and -171.9% net margin) and insiders sold 45,000 shares in the past 90 days.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $32.00 price objective on the stock. BTIG Research's target price would suggest a potential upside of 65.63% from the stock's previous close.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company upped their price target on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Friday, December 12th. Piper Sandler upped their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, December 12th. The Goldman Sachs Group set a $24.00 price objective on shares of Kestra Medical Technologies in a report on Friday, January 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Finally, Stifel Nicolaus set a $30.00 target price on shares of Kestra Medical Technologies in a report on Friday, December 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kestra Medical Technologies currently has an average rating of "Hold" and a consensus price target of $28.80.

Kestra Medical Technologies Trading Down 2.6%

Kestra Medical Technologies stock opened at $19.32 on Tuesday. Kestra Medical Technologies has a 52 week low of $13.25 and a 52 week high of $30.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. The stock has a market capitalization of $1.13 billion and a P/E ratio of -4.88. The stock has a 50-day simple moving average of $23.15 and a 200 day simple moving average of $24.59.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million for the quarter. Kestra Medical Technologies's revenue was up 62.7% on a year-over-year basis.

Insider Activity

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total value of $304,050.00. Following the sale, the insider owned 364,786 shares in the company, valued at approximately $7,394,212.22. This represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 45,000 shares of company stock worth $1,030,050 in the last 90 days. 3.60% of the stock is owned by insiders.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. grew its stake in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after buying an additional 474 shares in the last quarter. Brown Brothers Harriman & Co. raised its holdings in shares of Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock valued at $74,000 after purchasing an additional 656 shares in the last quarter. Rhumbline Advisers grew its position in shares of Kestra Medical Technologies by 7.3% in the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company's stock worth $307,000 after buying an additional 874 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in Kestra Medical Technologies during the 4th quarter worth approximately $31,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company's stock valued at $144,000 after buying an additional 1,392 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.